2 weeks Ago By ABMN Staff
2seventy bio, Inc. ( NASDAQ:TSVT – Get Free Report ) has been given an average recommendation of “Moderate Buy” by the nine ratings firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company.
The average 12 month price objective among brokers that have issued a report on the stock in the last year is $9.00. TSVT has been the subject of a number of analyst reports.
The Goldman Sachs Group lowered 2seventy bio from a “neutral” rating to a “sell” rating and lowered their price target for the company from $5.00 to $2.00 in a research report on Thursday, June 6th.
Morgan Stanley lowered their target price on shares of 2seventy bio from $7.00 to $6.00 and set an “equal weight” rating for the company in a report on Monday, July 29th.
Finally, Wedbush restated a “neutral” rating and set a $5.00 price target on shares of 2seventy bio in a report on Thursday, June 27th. Get Our Latest Report on TSVT Insider Transactions at 2seventy bio Hedge Funds Weigh In On 2seventy bio Large investors have recently modified their holdings of the business.
Stonepine Capital Management LLC bought a new position in 2seventy bio in the 2nd quarter worth approximately $385,000. SkyView Investment Advisors LLC lifted its position in shares of 2seventy bio by 25.0% during the second quarter.
SkyView Investment Advisors LLC now owns 12,500 shares of the company’s stock worth $48,000 after acquiring an additional 2,500 shares in the last quarter. Susquehanna Fundamental Investments LLC boosted its holdings in shares of 2seventy bio by 39.1% in the second quarter.
Susquehanna Fundamental Investments LLC now owns 192,319 shares of the company’s stock worth $740,000 after acquiring an additional 54,076 shares during the period. Marshall Wace LLP boosted its holdings in shares of 2seventy bio by 50.4% in the second quarter.
Marshall Wace LLP now owns 667,023 shares of the company’s stock worth $2,568,000 after acquiring an additional 223,408 shares during the period. Finally, Venator Management LLC grew its position in shares of 2seventy bio by 49.2% in the second quarter.
Venator Management LLC now owns 485,000 shares of the company’s stock valued at $1,867,000 after purchasing an additional 160,000 shares in the last quarter. Hedge funds and other institutional investors own 93.90% of the company’s stock.
2seventy bio Price Performance NASDAQ:TSVT opened at $4.93 on Thursday. 2seventy bio has a one year low of $1.
53 and a one year high of $6.40. The company has a market cap of $253.
90 million, a PE ratio of -1.13 and a beta of 1.77.
The firm has a 50-day moving average of $4.58 and a 200-day moving average of $4.52.
2seventy bio ( NASDAQ:TSVT – Get Free Report ) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.
35) by $0.06. 2seventy bio had a negative return on equity of 66.
01% and a negative net margin of 354.16%. The firm had revenue of $8.
97 million during the quarter, compared to analyst estimates of $11.43 million. On average, equities research analysts expect that 2seventy bio will post -1.
33 earnings per share for the current fiscal year. About 2seventy bio ( Get Free Report 2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.
Read More Receive News & Ratings for 2seventy bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 2seventy bio and related companies with MarketBeat.com's FREE daily email newsletter ..
